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Abstract: A significant challenge in toxicology is the ‘too many chemicals’ problem. Human beings and environmental species
are exposed to tens of thousands of chemicals, only a small percentage of which have been tested thoroughly using standard in
vivo test methods. This study reviews several approaches that are being developed to deal with this problem by the U.S. Environ-
mental Protection Agency, under the umbrella of the ToxCast programme (http://epa.gov/ncct/toxcast/). The overall approach is
broken into seven tasks: (i) identifying biological pathways that, when perturbed, can lead to toxicity; (ii) developing high-
throughput in vitro assays to test chemical perturbations of these pathways; (iii) identifying the universe of chemicals with likely
human or ecological exposure; (iv) testing as many of these chemicals as possible in the relevant in vitro assays; (v) developing
hazard models that take the results of these tests and identify chemicals as being potential toxicants; (vi) generating toxicokinet-
ics data on these chemicals to predict the doses at which these hazard pathways would be activated; and (vii) developing expo-
sure models to identify chemicals for which these hazardous dose levels could be achieved. This overall strategy is described
and briefly illustrated with recent examples from the ToxCast programme.
The last decade has seen a convergence of the need for alter-
natives to animal testing with the development and wide avail-
ability of large numbers of robust, high-throughput in vitro
assays. Such alternatives are needed because of the large num-
ber of chemicals in commerce with inadequate toxicological
information and concern about cost and animal welfare with
large-scale animal testing [1]. Even where high-quality, guide-
line animal studies are available, there is a need for human-
focused mechanistic information to help assess the human
relevance of any adverse findings.
The U.S. Environmental Protection Agency (U.S. EPA) is
contributing to the development and evaluation of high-
throughput in vitro alternative toxicology methods through the
ToxCastTM programme (ToxCast website: http://epa.gov/ncct/
toxcast/). ToxCast was initiated in 2007 with the goal of test-
ing a large and diverse set of environmentally relevant
chemicals in a correspondingly broad range of in vitro high-
throughput screening (HTS) and high-content screening (HCS)
assays [2]. The initial aim was to provide a data set that could
be used to evaluate the value of different assay technologies
and computational/modelling approaches. To date, ToxCast
has screened more than 1800 chemicals in as many as 700
assays. Several applications and modelling approaches have
been developed and published, mainly focusing on the first
300 ToxCast chemicals, which are primarily data-rich
pesticide active ingredients [3]. We are currently applying
these approaches to the larger Phase II data set, which
includes a more diverse set of chemicals. All of these data are
publically available, so researchers outside of the U.S. EPA
can perform independent evaluations and analyses through the
ToxCast website and the ToxCast dashboard (http://actor.epa.
gov/dashboard). ToxCast is one part of the U.S. multiagency
toxicity testing programme called Tox21, which comprises
researchers from the National Institutes of Health (NIH), the
National Toxicology Programme (NTP), the Food and Drug
Administration (FDA), and the U.S. EPA. Tox21 has many of
the same aims as ToxCast, but covers a broader chemical
space for a subset of HTS assay technologies [4].
A key element of the ToxCast/Tox21 paradigm is a focus
on the molecular and cellular pathways that are targets of
chemical interactions. By learning about these interactions and
their consequences to tissue and organ function, we can
manoeuvre tactically towards a more mechanistic understand-
ing, as opposed to merely what diseases or adverse health
effects are associated with potential chemical exposure. This
deeper understanding leads to increasing confidence in
identifying which populations might be at risk, significant sus-
ceptibility factors and key influences on the shape of the
dose–response curve. The high-level plan to achieve this can
be broken into seven major tasks: (i) identify biological path-
ways that, when sufficiently perturbed, can lead to specific
manifestations of toxicity; (ii) develop high-throughput in vitro
assays to test chemical perturbations of these pathways; (iii)
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identify the universe of chemicals with likely human or
ecological exposure (for the moment ignoring compounds in
development or not yet introduced into the environment); (iv)
test as many of these chemicals as possible in biologically rel-
evant in vitro assays; (v) build predictive models that take the
results of these tests and identify chemicals as being potential
toxicants; (vi) generate toxicokinetic data on these chemicals
to predict the doses at which these hazard pathways would be
activated; and (vii) develop exposure models to identify chem-
icals for which these hazardous dose levels could be achieved.
These steps are summarized in fig. 1.
This MiniReview briefly summarizes the main tasks carried
out in the ToxCast programme and lessons learned to date.
The results are focused largely on the published work from
Phase I of ToxCast, which tested about 300 chemicals, mostly
pesticidal active ingredients. Phase II, which extends testing to
as many as 1877 chemicals, is now close to completion, and
results are beginning to be released [5,6].
Materials and Methods
Chemicals. Chemicals for testing in ToxCast and Tox21 were
nominated by U.S. EPA, NIH, FDA, various stakeholder groups
(industry, academia and non-governmental organizations), international
governmental agencies and working groups of the Organisation for
Economic Co-operation and Development. The ToxCast Phase I
library contains 309 unique chemicals; the Phase II library contains
767 additional chemicals; and the E1K library (chemicals screened in
endocrine-related assays) comprises another 880 chemicals (totalling
1000 samples, hence the designation E (for endocrine) 1K). A number
of additional chemicals were added at several stages, so that the
current data set contains some screening data on 1877 unique
chemicals. The Tox21 list totals ~8200 chemicals, including
pesticides, pharmaceuticals, food additives and food contact
substances, cosmetics ingredients, personal care ingredients and
industrial chemicals [7]. The complete list of chemicals with identity
and structures can be found at the ToxCast website.
The testability and availability of chemicals are other important
considerations when selecting chemicals for the ToxCast testing
paradigm. In our current testing programme, all assays required that a
chemical be soluble and stable in DMSO (assays are optimized to use
DMSO-solubilized chemicals) and that it is not volatile (assays are
run in unsealed micro-titre plates, so volatile chemicals would escape).
We used calculated physico-chemical properties in an attempt to
exclude chemicals that do not meet these criteria, but a small fraction
of purchased chemicals fails at least one of these criteria based on fol-
low-up analytical testing. When chemicals are tested, they are solubi-
lized in DMSO and visually checked for the evidence of crystals or
particles. After solubilization, all chemicals are diluted into aqueous
buffer (to a final concentration of 100 lM) and analytically tested for
presence and purity of the intended structure. This process is still
ongoing but we see that approximately 5% of the compounds fail.
Chemicals that fail this QC process are flagged, but the data are not
removed. Failure could result from volatilization, degradation or poor
initial sample quality. Finally, chemical availability is an important
consideration. Many industrial chemicals are not available in small
and pure quantities (we aim for 95% purity but will accept lower val-
ues). Some compounds (especially pharmaceutical ingredients) are
excluded because they are very expensive or otherwise difficult to
procure.
The systematic cataloguing of chemicals, their uses and potential
exposure routes were a major driver in the development of the ACToR
database (Aggregated Computational Toxicology Resource, http://
actor.epa.gov). Currently, ACToR has four main modules: (i) ‘ACToR
main’; (ii) ToxRefDB; (iii) ToxCastDB; and (iv) ExpoCastDB [7,8].
The main portion of ACToR (‘ACToR main’) compiles data from
1359 public databases with information on hazard, exposure, risk
assessment, risk management, use, regulations and chemical properties
(all statistics are for the database release actor_2012q1). There are
551,763 chemicals in the database, although data coverage varies from
full data sets to very minimal information. The fact that many chemi-
cals have almost no public information that can help with risk assess-
ment is one of the main drivers of ToxCast and other screening
programmes. ToxRefDB catalogues data from guideline in vivo toxic-
ity studies and serves as the anchor for in vitro-to-in vivo modelling
efforts described below [9–11]. ToxCastDB contains HTS data from
ToxCast Phase I. ExpoCastDB provides data from biomonitoring stud-
ies [12]. The Chemical and Product Category (CPCat) database, which
compiles data from ACToR on chemical uses, is available at http://
actor.epa.gov/cpcat.
In vitro assays and testing of chemicals. In vitro assays were
obtained from commercial testing laboratories, in-house laboratories at
the U.S. EPA, collaborators at the NIH National Center for Advancing
Translational Science (NCATS) and academic partners. In total, there
are up to 700 assays or assay end-points being used as part of the
ToxCast programme. These cover a large range of technologies,
including cell-free biochemical assays, assays targeting nuclear and
other receptors and other molecular targets, assays measuring
downstream integrated cell processes and model organisms (especially
zebrafish) [5,6,13–24]. The complete set of assay descriptions can be
found at the ToxCast website. Where possible, the assays are
annotated with target gene and other metadata. With the exception of
a preliminary screen for a large number of cell-free biochemical
assays (the Novascreen assays), all assays are run in concentration–
response format. The Novascreen assays initially were run in duplicate
at a single concentration (50 lM for most assays and 25 lM for
cytochrome-P450 assays). If activity exceeded a pre-defined threshold,
the chemical–assay pair was repeated in concentration–response mode.
A customized data processing pipeline was developed to manage data
analysis from each of the assays, beginning with mapping well-level
data and continuing to chemical identification and concentration and
to curve fitting and hit calling (the process of deciding whether there
is a statistically significant concentration response). This process is
documented in the reference [25]. The complete data set (Phase I, II,
Fig. 1. Summary of the flow of major tasks in the ToxCast pro-
gramme that lead from initial identification of relevant biological path-
ways, inclusion of exposure information, to cost-efficient preliminary
risk assessments for thousands of chemicals.
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E1K) contains 1,526,359 chemical–assay pairs and is available at the
ToxCast website and dashboard.
Building of predictive models. For predictive model development, we
combined ToxCast in vitro data with in vivo toxicity data from
guideline studies compiled into ToxRefDB. Several preliminary first-
generation (Phase I) models have been published, including ones for
reproductive, developmental and chronic/cancer end-points [21,26–30].
These models used a combination of statistical and biologically based
modelling approaches.
Reverse toxicokinetics. Recently, several publications have applied in
vitro-to-in vivo extrapolation methods in pharmacokinetics to make
first-order predictions of the scaling from ingested dose to a
chemical’s plasma concentration [31–34]. This approach requires that
two experimental in vitro measurements be carried out: (i) clearance
of the parent chemical in primary hepatocytes and (ii) the unbound
fraction of the chemical present in the plasma. These measurements
can be carried out using either human or rat hepatocytes and plasma.
In a process called reverse toxicokinetics (RTK), a scaling factor is
calculated for each chemical that coverts a steady-state blood
concentration (Css) in micromoles to a daily dose in milligram per
kilogram per day. The scaling factor can then be applied to the AC50
values (the concentration at which 50% of maximal activity is seen) in
the in vitro assays to provide the daily dose that would be required to
activate that pathway.
Biological coverage of toxicities. The ToxCast/Tox21 groups
performed a broad survey of biological targets and pathways that,
when perturbed by chemicals, could lead to adverse outcome [4]. This
survey was focused on several modes of toxicity, namely endocrine
disruption, cancer, prenatal developmental outcome and reproductive
toxicity which includes fertility impairment. Many of the pathways
tested involve pharmaceutical targets that could lead to adverse effects
if improperly activated.
Simultaneously, the ToxCast/Tox21 groups surveyed the range of
assay technologies that were available in high-throughput mode. This
was motivated partly by the need to compare and contrast different
technologies for their utility and value in screening large numbers of
environmental chemicals. An early decision was made in ToxCast to
initially build the assay portfolio with large batteries of commercially
available HTS assays already used in the pharmaceutical industry
[2]. As such, the programme could begin testing much sooner and
over a broader assay space than would be possible if all assays were
developed de novo. Subsequent to the initial selection of assays for
Phase I of ToxCast, other assay sets have been added through col-
laborations with commercial suppliers, academic groups and in-house
laboratories at the U.S. EPA. Although the majority of the assays
that were run in Phase I of ToxCast yielded data that were useful
for further analyses, some were purged from the data set (or dis-
counted) because the data were noisy or otherwise unreliable. The
complete data set (excluding the purged data) is available as a col-
lection of files at the ToxCast website or through the ToxCast dash-
board.
Identifying the chemical universe. A long-term goal of the ToxCast
and Tox21 programmes is to test as many chemicals with potential for
human exposure as possible. Classes of chemicals of interest include
pesticidal active and inert ingredients; pharmaceuticals; industrial
chemicals; cosmetic and personal care ingredients; food additives and
contaminants and food contact substances; chemicals found in
furniture, paints and other household products; and chemicals found in
children’s products, such as clothes, bedding and toys. Cataloguing
chemicals, their uses and potential exposure routes were a major
driver in the development of the ACToR database.
Using data from ACToR, we compiled a list of 9912 chemicals that
were of high priority for screening, based on their use patterns [35].
These chemicals were largely limited to those subject to U.S. EPA
regulatory authority. Of them, two-thirds had no publicly available
toxicity/hazard data. A similar survey was carried out for the availabil-
ity of exposure data (occurrence in surface or drinking water, air, food
or soil; human biomonitoring data). A universe of 10,000 chemicals
was surveyed, and only about 1% had any relevant exposure data
[12]. Currently, we are carrying out a more complete survey of how
chemicals are used, based on data from the CPCat database (http://
actor.epa.gov/cpcat), to refine the universe of chemicals to test. The
present survey goes beyond U.S. EPA-regulated chemicals to include
a host of additional use classes listed in the previous paragraph. From
this analysis, we identified 41,866 chemicals with at least one known
use (e.g. industrial, consumer, etc.), of which 19,788 chemicals had at
least one consumer use. Future testing is expected to include chemi-
cals from this list.
Results
First-generation predictive models.
One key goal of the ToxCast programme is to discover corre-
lations and linkages between molecular/cellular perturbations
and apical toxicity end-points (adverse outcome). We approach
this problem by building in vitro/in vivo computational (in
silico) models. To do this, the ToxCast data are being com-
bined with in vivo toxicity data from guideline studies in U.S.
EPA’s ToxRefDB. Several first-generation (Phase I) models
have been published to date, including ones for reproductive,
developmental and chronic/cancer end-points [11,21,27–30,
36,37]. These models currently are being tested and refined
using the newest (Phase II) ToxCast data. An important point
about all of these models is that the in vitro data are mostly
from human cells, while the in vivo data are from rodents and
rabbits.
Reproductive toxicity model. Initial models of reproductive
toxicity were built using the data set compiled by Martin
et al. [10]. This data set compiled information on 75
reproductive effects for 256 chemicals with data from both
ToxCast and guideline multi-generation rat reproductive
guideline studies performed as part of pesticidal active
ingredient registrations. A total of 19 parental, offspring or
reproductive end-points had a sufficiently high incidence after
chemical exposure and were used as predictive end-points in
the model. These included reproductive performance indices,
male and female reproductive organ pathologies, offspring
viability, growth and maturation, and parental systemic
toxicities. Next, these end-points were combined with the
ToxCast data to build a model of generalized reproductive
toxicity. A reproductive toxicant was defined as a chemical
with a reproductive adverse effect seen at <500 mg/kg/day. A
total of 68 chemicals in the data set were considered to be
reproductive toxicants. Using the in vitro assay data from
ToxCast, a linear discriminant analysis (LDA) model was
constructed that predicted the reproductive toxicity with a
74% balanced accuracy (BA = mean of sensitivity and
specificity) based on cross-validation and a 76% BA using an
external validation set. The in vitro assays used in the model
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included activity in nuclear receptors [oestrogen receptor,
androgen receptor, peroxisome-proliferator-activated receptor
(PPAR)], cytochrome P450s, G-protein-coupled receptors and
other cell signalling pathways. This model was also evaluated
for its utility in prioritizing chemicals for further testing based
on a scenario where many chemicals were tested in vitro,
but where only a few could be tested in vivo because of cost
and animal welfare considerations [29]. Two regulatory
environments were evaluated in this study – one consistent
with industrial chemicals where little data are required to be
generated unless there is prior evidence of risk (screen in) and
another where many studies are required for registration, but
the U.S. EPA has the ability to waive (screen out) certain
studies.
Developmental toxicity model. Models of prenatal
developmental toxicity used data compiled from ToxRefDB on
guideline rat and rabbit developmental toxicity studies [9]. A
total of 383 rat and 368 rabbit studies were available, covering
387 chemicals, mostly pesticidal active ingredients. Of these
chemicals, 283 were tested in both species, and, of those, 53
chemicals were specifically developmentally toxic (no overt
maternal toxicity or maternal toxicity at doses higher than
observed for the developmental defects). The primary
expressions of developmental toxicity in pregnant rats were
foetal weight reduction, skeletal variations and abnormalities,
and foetal urogenital defects. Relative to rats, general
pregnancy/foetal losses were more frequently observed in the
rabbit as were structural malformations to the visceral body
wall and CNS. Species-specific models were built on these
data, linking in vitro ToxCast data to developmental defects
(LDA with cross-validation) [28]. Specifically, 271 chemicals
(187 unique) with ToxCast and ToxRefDB data were used,
with 251 for the rat model (146 identified as developmental
toxicants) and 234 for the rabbit model (106 identified as
developmental toxicants). A developmental toxicant was
defined as eliciting any significant end-point (i.e. foetal weight
reduction, various malformations, prenatal loss) regardless of
the maternal toxicity dose. The overall risk of a chemical
causing development defects was linked to disruption of the
following main targets and pathways: transforming growth
factor beta (TGFb), retinoic acid receptor (RAR) and G-protein-
coupled receptors in rat; and interleukins and chemokines in
rabbit. Species-specific models had a BA of about 70%. A key
finding was that the molecular effects driving prenatal
developmental toxicity showed strong species dependence in
prediction models for pregnant rats and rabbits. Because the
same set of in vitro assays was used for both species models,
the differences are assumed to reflect model input parameters
related to (i) the chemical space tested in each species; (ii) the
apical end-points (in vivo outcome) recorded for each species,
toxicokinetic differences between rats and rabbits, and/or
toxicodynamic differences between the responses in pregnant
dams and their conceptuses for either species.
Developmental vascular disruption model. Several of the
molecular targets that were associated with developmental
defects suggested a broad linkage between disruption of
vascular development and the emergence of gross phenotypic
developmental defects. This hypothesis led to the concept of
‘putative vascular disrupting compounds’ (pVDCs)
[9,26,27,38]. An AOP linking multiple molecular initiating
events to outcome was developed around the biomedical
literature and Mouse Genome Informatics (MGI) database to
provide a framework for identifying pVDCs based on ToxCast
in vitro signatures. Particular targets included inflammatory
chemokine signalling (CK), the vascular endothelial growth
factor (VEGF) pathway and the plasminogen-activating system
(uPAR). Consistent with the species dependence of prediction
models built for prenatal developmental toxicity in pregnant
rats and rabbits [28], we also observed species differences in
models predicting pathway-level sensitivity to angiogenic
signals, particularly those mediated by CK and uPAR
pathways. This suggests a mechanistic link to species-
dependent processes for inflammatory responses and
extracellular (ECM) remodelling, respectively. The group of
pVDCs with rat developmental toxicity correlated with down-
regulation of pro-inflammatory CK assays, whereas pVDCs
with rabbit activity often resulted in up-regulation of these
signals. The rabbit pVDCs generally showed greater
bioactivity across assays, which can be inferred to entail ECM
degradation and release of angiogenic growth factors. The
observed in vivo developmental toxicity also showed a distinct
trend across species, with skeletal malformation in rats and
prenatal death in rabbits being the most prevalent end-points
for the pVDCs [27]. To further investigate this linkage, a cell/
tissue-level dynamic signalling in silico model was developed
[26] using the CompuCell3D (CC3D) software (http://www.
compucell3d.org/). The in silico model was able to
recapitulate self-directed assembly of endothelial cells into a
completed vascular network utilizing signal-response pathways
involving an exchange of CK, VEGF and uPAR among
several cell types. By incorporating parameters from ToxCast
HTS data into this ‘virtual tissue model’, the concentration-
dependent disruption of angiogenesis was shown for 5HPP-33,
an anti-angiogenic thalidomide analogue (fig. 2).
Cancer model. We have also published a first-generation
prediction model linking in vitro effects and the likelihood
that a chemical will be an in vivo carcinogen [36]. This model
began with the hypothesis that chemicals perturbing cancer
hallmark processes would increase the likelihood of those
chemicals being carcinogens [39,40]. To test this hypothesis,
univariate associations were calculated between each gene
tested by the ToxCast assays and each cancer end-point (rat or
mouse) in ToxRefDB. We found that the vast majority of
cancer-linked genes (defined as having an odds-ratio >2, with
confidence intervals not overlapping with zero after
permutation testing) were either hallmark-associated or
involved in xenobiotic metabolism. A scoring function was
used that combined the cancer-associated gene hits for each
chemical into an overall score. This was applied to an external
test set of 33 chemicals that were not used in the model
development process. The results were that the model
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distinguished between carcinogens and non-carcinogens with
statistical significance (p = 0.024). Future work on all of the
models will expand them to look in more detail at the
molecular mechanisms linked to the adverse outcome and to
forward validate using ToxCast Phase II data.
In vitro pharmacokinetics – reverse toxicokinetics.
To improve the accuracy of quantitative predictions of in vivo
toxicity, it is necessary to have appropriate pharmacokinetic
(PK) models [31,32,34,41]. New methods and models are
being developed that increase throughput and efficiency and
allow generation of simple PK data for hundreds of chemicals
[41]. Measurements of clearance of the parent chemical in pri-
mary hepatocytes and the fraction unbound in the presence of
plasma protein can be carried out using either human or rat
hepatocytes and plasma. These experimental values are inputs
to in vitro-to-in vivo extrapolation models, and the conversion
of steady-state serum concentrations to administered dose
using RTK. One use of this approach has been to compare
doses at which each of the ToxCast assays would be predicted
to be activated with the predicted doses from pesticide resi-
dues in the human diet [31,32,34,41]. This calculation showed
that, for almost all pesticidal ingredients, no measured path-
way would be activated, which is defined as a concentration
reaching the AC50 for an assay, at the expected doses. One
notable exception is triclosan, which has intentional exposures
through its use in soaps, toothpaste and other consumer prod-
ucts. Note that the choice of the AC50 as a metric for the acti-
vating concentration is one of several points of departure that
could be used. For the thirteen chemicals where human-rele-
vant data (either PBPK models or actual serum measurements)
is available, the steady-state serum predictions of the RTK
method have been evaluated. For eight of the thirteen chemi-
cals, the predictions were on the order of the data, while for
the other cases, the predictions differed by orders of magni-
tude. The RTK predictions were conservative for all but per-
fluorinated compounds, which are hypothesized to be actively
reabsorbed by the kidney after glomerular filtration [31].
High-throughput exposure modelling.
In order to perform risk assessments on the large numbers of
chemicals to which human beings are exposed, we need meth-
ods for estimating exposures that are as high-throughput as
HTS methods are for estimating hazard. To meet this need,
we are developing high-throughput exposure models for this
type of application under the U.S. EPA ExpoCast programme.
Important aspects of these models are accurate statistical eval-
uation and estimation of uncertainties [42]. Exposure is a con-
sequence of many factors, including human activity and the
environment (both inside and outside of the home). To be
high-throughput, exposure models must assume that chemicals
can be described using only those parameters that can be
Fig. 2. Cellular systems-based simulation of endothelial cell organization into a complete endothelial network using CompuCell3D. Results com-
paring in silico disruption for 5HPP-33 based on ToxCast data (upper panel) versus a human angiogenesis (human umbilical vein endothelial cells
– HUVEC) assay (lower panel). The middle and right panels show increasing lack of vascular organization with increasing dose. Reprinted from
Kleinstreuer, Dix et al. 2013 [26].
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obtained easily. Depending on the specific model, these
assumptions may be correct for some, none or all chemicals
evaluated. The ExpoCast model evaluation framework treats
ensembles of models as related assays for predicted chemical
exposure. To evaluate the predictivity of a given model, evalu-
ation sets must be obtained. Given that directly measuring
human exposure is difficult, exposure has been inferred from
biomonitoring data using simple pharmacokinetic models. This
inference process is fraught with additional assumptions and is
also a contributor to overall uncertainty in model predictions.
With careful analysis, it has been shown that current models
can be 95% confident that exposures lie within roughly eight
orders of magnitude (e.g. 0.01 lg/kg/BW/day to 1 g/kg/BW/
day) band, but that the upper 95% limit for roughly a third of
1936 chemicals evaluated to date was below the lowest oral
equivalent dose identified by Wetmore and coworkers
[31,32,34]. As both exposure prediction and biomonitoring
exposure inference models improve, it is expected that uncer-
tainty will continue to be reduced, enabling rapid risk-based
prioritization of chemicals.
High-throughput risk assessment: combining the pieces.
A long-term goal of the ToxCast and related programmes is
to develop methods for carrying out quantitative risk assess-
ments in the absence of in vivo animal data. One key piece is
an estimate of a no-effect level (NEL) for a chemical (e.g. a
no-adverse-effect level) (NOAEL) or an NEL adjusted for
uncertainty factors (e.g. a reference dose, RfD). The other is
an estimate of the expected exposure level. Our approach to
this latter quantity was outlined in the previous section. Here,
we describe our initial approach to determining in vitro equiv-
alents of an NEL or an RfD [33]. Firstly, because in vitro data
are generated target by target or pathway by pathway, we
derive a lowest concentration at which a particular pathway is
altered, called the biological-pathway-altering concentration
(BPAC). This quantity is divided by the scaling factor derived
from the RTK modelling described above, to generate the
biological-pathway-altering dose (BPAD). Both the BPAC and
the scaling factor are subject to various types of uncertainty
and population variability, which yield a distribution of the
BPAD. We then take the lower end of the BPAD distribution
(BPAD-L) as the pathway-wise equivalent of the RfD. This
approach was demonstrated by calculating the BPAD-L for a
set of conazole fungicides with the end-point being pregnane-
X-receptor (PXR)-related liver hypertrophy. These values were
all within a factor of 10 of the in vivo equivalent, and most
were more conservative (BPAD-L < RfD) [33].
Discussion
We have briefly summarized the results derived from Phase I
of the ToxCast project. The goals of Phase I largely have been
met and include the following: (i) demonstrating that a large
set of environmentally relevant chemicals can be screened in a
diverse battery of in vitro assays; (ii) that predictive models
of toxicity can be developed using these data; and (iii) that
in vitro pharmacokinetic data can be integrated with the in vi-
tro assay data, enabling us to make initial quantitative compar-
isons with in vivo rodent toxicity data.
That said, a number of challenges lie ahead. Some of these
have been outlined by other researchers who performed inde-
pendent analyses of the ToxCast data [43,44]. One challenge
is presented by the broad diversity of chemicals, chemical–
biological activities in vitro and chemical effects in vivo. At
the very least, these pose a classic statistical power issue. For
instance, if there are N different mechanisms by which a
chemical can cause a specific phenotype, one needs a signifi-
cant multiple of N examples for each such pathway-end-point
pair in the data set to discover this linkage using purely statis-
tical methods [37]. This argues for the need to increase the
size of the data set (number of chemicals), which we are
beginning to do with Phase II of ToxCast. This presents
increasing challenges, however, because the number of chemi-
cals with high-quality toxicity data (typically using guideline
studies) has not increased as rapidly, simply because there is
such a limited amount of these data available. A second chal-
lenge is how to link in vitro activity and in vivo effects.
Purely, statistical methods that treat the data as just a set of
numbers, in the same way that quantitative structure–activity
relationship (QSAR) models are built, have inherent limita-
tions [43,44]. One approach to solve this problem is to
develop network models of adverse outcome pathways or
modes of action [41,45–49]. These help form hypotheses for
statistical testing, and also help minimize the multiple testing
issues inherent in the purely statistical approach.
Another solution to both of these issues is to develop and
employ more complex, cellular and multi-scale, biologically
based models that incorporate information and knowledge of
the structure of the biological pathways being altered that
include pharmacokinetic information and that explicitly
include multiple levels of biological organization [9,26,27,50–
53]. This is the driver of our virtual tissue modelling research
(http://www.epa.gov/ncct/v-Embryo/ http://www.epa.gov/ncct/
virtual_liver/).
A complementary approach is to use in vitro data and
model data in a tiered manner with risk-based metrics driving
the elevation to higher tiers [33,41]. These approaches could,
for instance, use point of departure metrics to guide further
testing, and for many chemicals short circuit the need to focus
on specific hazard identification. This is because expected
exposures are likely much lower than the in vitro-derived
point of departure. We suspect that this will leave a signifi-
cantly smaller set of chemicals for which more complex, bio-
logically based models, and follow-up testing, will be needed.
There is also a potential (although this is unproven) that there
are a relatively small set of critical pathways that will then be
active in these remaining chemicals at relevant concentrations.
While these challenges are daunting, new modelling and in
vitro methods and computational models provide avenues for
improvement to existing methods. These efforts will improve
risk predictions for human beings and ecosystem health for
thousands of currently untested chemicals.
Published 2014. This article is a U.S. Government work and is in the public domain in the USA
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